Truist Securities Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $35
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $27 to $35.
Truist Securities analyst Richard Newitter upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $27 to $35.